Ocular Hypertension Treatment Study (OHTS)

Overview

About this study

To determine whether medical reduction of intraocular pressure prevents or delays the onset of glaucomatous visual field loss and/or optic disc damage in ocular hypertensive participants judged to be at moderate risk for developing open-angle glaucoma. To produce natural history data to assist in identifying patients at most risk for developing open-angle glaucoma and those most likely to benefit from early medical treatment. To quantify risk factors for developing open-angle glaucoma among ocular hypertensive individuals.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Men and nonpregnant women between the ages of 40 and 80 
  • IOP greater than or equal to 24 mm Hg but less than or equal to 32 mm Hg in at least one eye and IOP greater than or equal to 21 but less than or equal to 32 mm Hg in the fellow eye
  •  Normal visual fields
  • Optic discs are eligible for the trial

Exclusion Criteria:

  • Patients presenting with best-corrected visual acuity worse than 20/40 in either eye
  • Previous intraocular surgery
  • A life-threatening or debilitating disease
  • Secondary causes of elevated IOP
  • Angle-closure glaucoma or anatomically narrow angles
  • Other diseases that can cause visual field loss
  • Background diabetic retinopathy
  • Optic disc abnormalities that can produce visual field loss or obscure the interpretation of the optic disc
  • Unwillingness to undergo random assignment

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Cheryl Khanna, M.D.

Closed for enrollment

Contact information:

Jane Sultze CCRP

(507) 538-5523

Sultze.Jane@mayo.edu

More information

Publications

Publications are currently not available